A detailed history of Jpmorgan Chase & CO transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Jpmorgan Chase & CO holds 8,424 shares of BCYC stock, worth $123,664. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,424
Previous 6,642 26.83%
Holding current value
$123,664
Previous $134,000 42.54%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$19.58 - $27.24 $34,891 - $48,541
1,782 Added 26.83%
8,424 $191,000
Q2 2024

Aug 12, 2024

SELL
$20.02 - $24.69 $179,098 - $220,876
-8,946 Reduced 57.39%
6,642 $134,000
Q1 2024

May 10, 2024

BUY
$16.75 - $26.1 $91,823 - $143,080
5,482 Added 54.25%
15,588 $388,000
Q4 2023

Feb 12, 2024

SELL
$13.29 - $22.2 $776,042 - $1.3 Million
-58,393 Reduced 85.25%
10,106 $182,000
Q3 2023

Nov 14, 2023

SELL
$19.9 - $26.25 $550,274 - $725,865
-27,652 Reduced 28.76%
68,499 $1.38 Million
Q2 2023

Aug 11, 2023

BUY
$18.95 - $28.67 $170,796 - $258,402
9,013 Added 10.34%
96,151 $2.45 Million
Q1 2023

May 11, 2023

BUY
$20.02 - $31.37 $78,718 - $123,346
3,932 Added 4.73%
87,138 $1.85 Million
Q4 2022

Feb 13, 2023

SELL
$20.37 - $32.9 $865,378 - $1.4 Million
-42,483 Reduced 33.8%
83,206 $2.46 Million
Q3 2022

Nov 14, 2022

BUY
$17.49 - $28.44 $738,620 - $1.2 Million
42,231 Added 50.6%
125,689 $2.92 Million
Q2 2022

Aug 11, 2022

BUY
$12.95 - $46.99 $952,537 - $3.46 Million
73,555 Added 742.75%
83,458 $1.4 Million
Q1 2022

May 11, 2022

BUY
$40.12 - $59.5 $283,849 - $420,962
7,075 Added 250.18%
9,903 $434,000
Q4 2021

Feb 10, 2022

BUY
$41.7 - $61.14 $61,007 - $89,447
1,463 Added 107.18%
2,828 $172,000
Q3 2021

Nov 12, 2021

BUY
$27.95 - $44.24 $38,151 - $60,387
1,365 New
1,365 $57,000

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $436M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.